# Relative Bioavailability of 2 Oral Formulations of Nintedanib

> **NCT02572752** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 70 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Nintedanib
- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT02572752
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02572752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02572752, "Relative Bioavailability of 2 Oral Formulations of Nintedanib". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT02572752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*